Endometriosis and Weight: Can GLP-1 Help?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Endometriosis impacts roughly 10% of reproductive-age women, and many experience unwanted weight gain alongside pelvic pain and fatigue. This connection between endometriosis and weight gain stems from chronic inflammation, altered hormone signaling, and changes in appetite regulation. GLP-1 therapies may address the metabolic side of this complex condition.

Understanding Endometriosis and Weight Gain

Endometriosis causes tissue similar to the uterine lining to grow outside the uterus, triggering systemic inflammation throughout the body. This inflammatory state disrupts appetite hormones, increases insulin resistance, and slows metabolic rate—all factors that promote weight accumulation. Women with endometriosis often report gaining 5–15 pounds despite no change in eating habits, a frustration that reflects real metabolic dysfunction rather than personal failure.

Hormonal shifts in endometriosis also affect leptin and ghrelin, the hormones that signal fullness and hunger. Elevated estrogen levels amplify this dysregulation, making satiety harder to achieve and calorie restriction more difficult to sustain. Compounding this, chronic pain limits physical activity, further reducing daily energy expenditure and creating a cycle that favors weight gain.

How GLP-1 Medications Address Appetite and Inflammation

GLP-1 receptor agonists like semaglutide work by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar, slows gastric emptying, and sends fullness signals to the brain. By enhancing these natural pathways, semaglutide reduces hunger intensity and portion sizes without requiring willpower alone. For people with endometriosis-related weight gain, this mechanism directly counteracts the appetite dysregulation caused by chronic inflammation.

Research suggests GLP-1 agonists may also lower inflammatory markers, including C-reactive protein and interleukin-6, both elevated in endometriosis. By reducing systemic inflammation, these medications address a root cause of metabolic dysfunction rather than treating weight as an isolated symptom. This dual action—appetite suppression plus anti-inflammatory benefit—makes GLP-1 therapy particularly relevant for endometriosis patients seeking sustainable weight management.

Clinical Evidence for GLP-1 Use in Endometriosis

While large randomized trials specifically studying GLP-1 agonists in endometriosis populations remain limited, existing evidence supports the biological rationale. Studies show semaglutide produces 10–15% body weight reduction in general populations, with stronger results in individuals with insulin resistance—a hallmark of endometriosis. Additionally, data from metabolic syndrome and PCOS (polycystic ovary syndrome, which shares inflammatory features with endometriosis) demonstrate GLP-1 agonists improve both weight and hormonal health.

The PlexusDx Precision Peptide Genetic Test reports on variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Semaglutide Injection: Accessible, Personalized Treatment

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), with no insurance required and HSA/FSA eligibility. The medication is manufactured by licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality and sterility. Semaglutide is available across all 50 states, making treatment accessible whether you live in a rural area or major city.

Dosing begins low and increases gradually based on your response and tolerance, allowing your healthcare provider to find your optimal dose. PlexusDx pricing remains flat regardless of dose level—your dose may need to go up, but your price won't—removing a common barrier to dose optimization. Combined with PlexusDx's telehealth consultations, treatment becomes convenient and affordable for managing endometriosis-related weight gain.

Genetic Testing and Personalized Peptide Therapy Selection

PlexusDx offers the Precision Peptide Genetic Test ($298) to map your unique peptide-pathway genetics. This test examines 49 peptides across 14 metabolic and hormonal pathways, including critical variants like GIPR rs1800437 and FTO rs9939609. Understanding your genetic predispositions helps explain why endometriosis weight gain affects you specifically and which medication class may work best.

For endometriosis patients considering semaglutide, genetic insights into your leptin and insulin signaling pathways inform whether monotherapy is sufficient or whether PlexusDx's GLP-Squared dual-compound injection (combining semaglutide and tirzepatide) might offer greater metabolic coverage. This precision approach reduces guesswork and accelerates your path to sustainable weight loss while managing your condition.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can GLP-1 medications treat endometriosis pain directly?

GLP-1 agonists do not treat endometriosis pain itself; they target weight management and metabolic inflammation. However, by reducing systemic inflammation and supporting weight loss, they may indirectly ease some pain-related symptoms. Always discuss endometriosis pain management with your gynecologist or pain specialist alongside weight-loss therapy.

Will semaglutide interfere with fertility or endometriosis treatment?

Semaglutide does not directly affect fertility or contraceptive efficacy. However, if you are actively trying to conceive or undergoing endometriosis-related fertility treatment, discuss GLP-1 therapy with your reproductive endocrinologist to ensure coordinated care. Weight loss from semaglutide may improve fertility outcomes in some cases.

How much weight can I expect to lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to GLP-1 medications or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is compounded semaglutide from PlexusDx as effective as brand-name Wegovy?

PlexusDx compounded semaglutide is manufactured by licensed 503A compounding pharmacies and contains the same active ingredient as brand medications. Efficacy depends on proper storage, consistent dosing, and individual genetic factors—not brand name. Your PlexusDx provider adjusts dosing based on your response, optimizing outcomes.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's Precision Peptide Genetic Test identifies 14 pathways and 150+ genetic insights. If your GLP1R or GIPR variants suggest limited response, PlexusDx can recommend alternative or combination therapies—such as GLP-Squared (semaglutide + tirzepatide) or oral tirzepatide—to match your genetic profile and maximize results.

Does PlexusDx require insurance or membership fees?

No. PlexusDx serves all 50 states with no insurance requirement and no membership fees. Compounded semaglutide is $189/mo month-to-month, or from $149/mo on the 6-month plan and is HSA/FSA eligible, making treatment affordable and accessible regardless of insurance status.

Related Reading

• Glp 1 For Losing Weight
• Glp 1 For Endometriosis
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.